Genome & Company (KOSDAQ: 314130)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,915.00
-15.00 (-0.51%)
Nov 15, 2024, 9:00 AM KST
-51.90%
Market Cap 90.43B
Revenue (ttm) 23.92B
Net Income (ttm) -37.88B
Shares Out 30.97M
EPS (ttm) -1,297.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 224,281
Open 2,895.00
Previous Close 2,930.00
Day's Range 2,710.00 - 2,985.00
52-Week Range 2,710.00 - 7,335.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, co... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 314130
Full Company Profile

Financial Performance

In 2023, Genome & Company's revenue was 14.30 billion, an increase of 1.50% compared to the previous year's 14.08 billion. Losses were -47.47 billion, -8.43% less than in 2022.

Financial Statements

News

There is no news available yet.